Major Depression
Dr. John Goethe is conducting a new trial using a new, non-invasive medical device for the treatment of depression known as transcranial magnetic stimulation. Inclusion criteria for the trial include a diagnosis of Major Depressive Disorder, failure to respond to exactly one medication in the current Major Depressive Episode and age between 22 and 65 years old. The trial consists of five treatments per week for six weeks. Each treatment takes approximately 30 minutes. There is no recovery period, so the patient is free to leave at the conclusion of each treatment.
For more information, please contact:
Sherri L. Post
phone: (860) 545-7502
email: spost@harthosp.org
Dr. Andrew Winokur is an investigator participating in a Phase II clinical research study to investigate whether a twice weekly dose regimen of ketamine will be as effective in sustaining the reduction of depressive symptoms in therapy resistant depression as a 3-times-weekly dose regimen. Inclusion criteria for the study include man or woman, 18 to 64 years of age, a diagnosis of recurrent Major Depressive Disorder wihtout psychotic features, and an inadequate response to at least one antidepressant in the current episode of depression and at least one other inadequate treatment response to an antidepressant either in the current episode or in a previous episode.
For more information, please contact:
Andrew Winokur, M.D., Ph.D.
phone: (860) 545-7502
email: awinokur@uchc.edu
Have you been diagnosed with Major Depression? Has your depression not improved with your current medication? Dr. John Goethe at The Institute of Living/Hartford Hospital is offering screenings for participation in a clinical research study to assess whether an investigational drug may be useful, safe and well-tolerated for the treatment of major depression. Participants will receive a study-related psychiatric evaluation and the study drug at no cost.
For more information, please contact:
Sherri L. Post
phone: (860) 545-7502
email: spost@harthosp.org
(top)
Neuroimaging Studies
The Olin Neuropsychiatry Research Center is at the forefront of research in applying quantitative measures of brain structure and function to neuropsychiatric themes, especially to severe mental illnesses, such as schizophrenia. Techniques include structural and functional MRI. In addition, electrophysiologic measures, including event-related potential assessments, are an important feature of our research.
To learn more about the studies currently being conducted,
click here or contact:
Obsessive-Compulsive Disorder
The Anxiety Disorders Center at The Institute of Living/Hartford Hospital is conducting studies of people with obsessive-compulsive disorder including a neuroimaging (brain scan) study, an interview study, and a study examining problem solving abilities.
Schizophrenia
Two studies testing the effects of a novel adjunctive therapy for the treatment of either sub-optimal response or negative symptom schizophrenia are being conducted by Drs. Goethe and Winokur.
For more information about these trials, please contact:
Sherri L. Post
phone: (860) 545-7502
email: spost@harthosp.org
(top)
Schizophrenia in Adolescents
The Burlingame Center is currently recruiting patients 12-18 years of age for a clinical trial testing the safety and efficacy of asenapine treatment for adolescents with schizophrenia.
For more information about this trial, please contact:
Sherri L. Post
phone: (860) 545-7502
email: spost@harthosp.org
(top)